PITTSBURGH, Sept. 7, 2011 /PRNewswire/ -- Precision Therapeutics will present data on four compelling multi-gene breast cancer signatures at the 2011 Breast Cancer Symposium, being held September 8-10, 2011, in San Francisco, California. Precision's abstract, titled, "Evaluation of the Performance of Breast Cancer Cell-Line Derived Multi-Gene Predictors (MGPs) of Chemotherapy Response in Multiple Clinical Trials," demonstrates the feasibility of using these signatures to predict chemotherapy response in breast cancer patients.
Using cancer cell lines to identify pharmacogenomic predictors of patient clinical outcomes may be faster and less costly to perform than utilizing gene expression data from a prospectively collected patient cohort, according to the authors of the abstract.
"Identifying individual patients that are most responsive to specific chemotherapy regimens is clinically useful," says Nan Song, Bioinformatics and Statistic Scientist at Precision Therapeutics. "By combining ChemoFx® chemosensitivity data from cell lines with their genomic profiles, we have developed four unique Multi-Gene Predictors for chemotherapy response from breast cancer cell lines and performed a systematic evaluation of the performance of these gene signatures using data from five distinct clinical trials. The promising results give us hope for helping optimize treatments for breast cancer patients."
About Precision Therapeutics
Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum.
Precision's state of the art Comprehensive Tumor Profiling is an integrated straightforward approach combining three core platforms of personalized medicine to capture the total sum of genomic, proteomic and functional information for each patient's cancer through a portfolio of multi-platform tests for cancer treatment in multiple tumor types.
Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. Precision currently receives ChemoFx® specimens from 271 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care. To date, ChemoFx® Patient Reports have been provided for over 60,000 patient specimens, using 105 unique chemotherapy treatments and combinations.
For more information, visit www.precisiontherapeutics.com or www.chemofx.com.
SOURCE Precision Therapeutics